Search results
Showing 121 to 135 of 539 results for syndrome
Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (HTG253)
Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.
View recommendations for HTG253Show all sections
Sections for HTG253
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.
compared to symptomatic treatment for people with major low anterior resection syndrome? Any explanatory notes(if applicable) Why the...
strategy for preventing the development of excessive weight gain and metabolic syndrome associated with the use of antipsychotic...
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
guide outlines how we develop our PDAs. PDAs by condition Cancer Lynch syndrome: should I take aspirin to reduce my chance of getting...
Evidence-based recommendations on the serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children. This involves cutting and stapling the bowel in a zig-zag pattern to narrow and lengthen it.
View recommendations for HTG149Show all sections
Sections for HTG149
Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.
View recommendations for TA322Show all sections
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.
Awaiting development Reference number: GID-TA11910 Expected publication date: TBC
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (HTG391)
Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.
This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
This indicator covers the percentage of male patients with diabetes who have a record of erectile dysfunction with a record of advice and assessment of contributory factors and treatment options in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM52
Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]
Awaiting development Reference number: GID-TA11821 Expected publication date: TBC